320 related articles for article (PubMed ID: 34160824)
1. Assessment of gender representation in clinical trials leading to FDA approval for oncology therapeutics between 2014 and 2019: A systematic review-based cohort study.
Dymanus KA; Butaney M; Magee DE; Hird AE; Luckenbaugh AN; Ma MW; Hall ME; Huelster HL; Laviana AA; Davis NB; Terris MK; Klaassen Z; Wallis CJD
Cancer; 2021 Sep; 127(17):3156-3162. PubMed ID: 34160824
[TBL] [Abstract][Full Text] [Related]
2. Race and Ethnicity Reporting and Enrollment Disparities in Clinical Trials Leading to FDA Approvals for Breast Cancer Between 2010 and 2020.
Nguyen RH; Silva Y; Lu J; Chen Z; Gadi V
Clin Breast Cancer; 2023 Aug; 23(6):591-597. PubMed ID: 37296063
[TBL] [Abstract][Full Text] [Related]
3. Racial/Ethnic Disparities in Ophthalmology Clinical Trials Resulting in US Food and Drug Administration Drug Approvals From 2000 to 2020.
Berkowitz ST; Groth SL; Gangaputra S; Patel S
JAMA Ophthalmol; 2021 Jun; 139(6):629-637. PubMed ID: 33885724
[TBL] [Abstract][Full Text] [Related]
4. The impact of the globalization of cancer clinical trials on the enrollment of Black patients.
Tharakan S; Zhong X; Galsky MD
Cancer; 2021 Jul; 127(13):2294-2301. PubMed ID: 33682111
[TBL] [Abstract][Full Text] [Related]
5. Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018.
Loree JM; Anand S; Dasari A; Unger JM; Gothwal A; Ellis LM; Varadhachary G; Kopetz S; Overman MJ; Raghav K
JAMA Oncol; 2019 Oct; 5(10):e191870. PubMed ID: 31415071
[TBL] [Abstract][Full Text] [Related]
6. Sex Representation in Clinical Trials Associated with FDA Cancer Drug Approvals Differs Between Solid and Hematologic Malignancies.
Mendis S; Anand S; Karasinska JM; Dasari A; Unger JM; Gothwal A; Ellis LM; Varadhachary G; Kopetz S; Overman MJ; Raghav K; Loree JM
Oncologist; 2021 Feb; 26(2):107-114. PubMed ID: 32960478
[TBL] [Abstract][Full Text] [Related]
7. An Evaluation of Sex- and Gender-Based Analyses in Oncology Clinical Trials.
Hall M; Krishnanandan VA; Cheung MC; Coburn NG; Haas B; Chan KKW; Raphael MJ
J Natl Cancer Inst; 2022 Aug; 114(8):1186-1191. PubMed ID: 35477781
[TBL] [Abstract][Full Text] [Related]
8. Differential treatment effect between younger and older adults for new cancer therapies in solid tumors supporting US Food and Drug Administration approval between 2010 and 2021.
Wilson BE; Desnoyers A; Nadler MB; Amir E; Booth CM
Cancer; 2023 Oct; 129(20):3318-3325. PubMed ID: 37340792
[TBL] [Abstract][Full Text] [Related]
9. Cancer Disparities and Black American Representation in Clinical Trials Leading to the Approval of Oral Chemotherapy Drugs in the United States Between 2009 and 2019.
Ajewole VB; Akindele O; Abajue U; Ndulue O; Marshall JJ; Mossi YT
JCO Oncol Pract; 2021 May; 17(5):e623-e628. PubMed ID: 33974825
[TBL] [Abstract][Full Text] [Related]
10. FDA Approvals of Oncology Drugs for Tissue-Agnostic Indications.
Zettler ME
Target Oncol; 2023 Sep; 18(5):777-792. PubMed ID: 37477750
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration.
Hilal T; Sonbol MB; Prasad V
JAMA Oncol; 2019 Jun; 5(6):887-892. PubMed ID: 31046071
[TBL] [Abstract][Full Text] [Related]
12. Food and Drug Administration approvals in phase 3 Cancer clinical trials.
Abi Jaoude J; Kouzy R; Ghabach M; Patel R; Pasalic D; Ghossain E; Miller AB; Lin TA; Verma V; Fuller CD; Subbiah V; Minsky BD; Ludmir EB; Taniguchi CM
BMC Cancer; 2021 Jun; 21(1):695. PubMed ID: 34118915
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of sex and racial subgroup participation rates and differential treatment effects for trials in solid tumor malignancies leading to US Food and Drug Administration registration between 2010 and 2021.
Wilson BE; Nadler MB; Desnoyers A; Booth CM; Amir E
Cancer; 2024 Jan; 130(2):276-286. PubMed ID: 37751315
[TBL] [Abstract][Full Text] [Related]
14. Ten-Year Trends in Enrollment of Women and Minorities in Pivotal Trials Supporting Recent US Food and Drug Administration Approval of Novel Cardiometabolic Drugs.
Khan MS; Shahid I; Siddiqi TJ; Khan SU; Warraich HJ; Greene SJ; Butler J; Michos ED
J Am Heart Assoc; 2020 Jun; 9(11):e015594. PubMed ID: 32427023
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of race/ethnicity in trials leading to anti-rheumatic drug approval for inflammatory arthritis by the US Food and Drug Administration.
Xie Y; Liu Y; Qin Y; Chen X; Xie Q
Int J Rheum Dis; 2023 Dec; 26(12):2489-2497. PubMed ID: 37854006
[TBL] [Abstract][Full Text] [Related]
16. Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials.
Chen EY; Joshi SK; Tran A; Prasad V
JAMA Intern Med; 2019 May; 179(5):642-647. PubMed ID: 30933235
[TBL] [Abstract][Full Text] [Related]
17. Challenges with sex-specific subgroup analyses in oncology clinical trials for drug approvals between 2015-2020.
Jenei K; Raymakers A; Meyers DE; Prasad V
J Cancer Policy; 2021 Dec; 30():100311. PubMed ID: 35559802
[TBL] [Abstract][Full Text] [Related]
18. Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021.
Benjamin DJ; Xu A; Lythgoe MP; Prasad V
JAMA Netw Open; 2022 Mar; 5(3):e222265. PubMed ID: 35289858
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019.
Dhodapkar M; Zhang AD; Puthumana J; Downing NS; Shah ND; Ross JS
JAMA Netw Open; 2021 Jun; 4(6):e2113224. PubMed ID: 34110392
[TBL] [Abstract][Full Text] [Related]
20. Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018.
DeMartino PC; Miljkovic MD; Prasad V
JAMA Intern Med; 2021 Feb; 181(2):162-167. PubMed ID: 33165499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
